US Stocks Movement: Vaxcyte surged on October 5 as VAX-31 Phase III achieved targets and pneumonia vaccine progress

Vaxcyte Soared on October 5: Interpretation

Keywords: VAX-31 Phase III Met Primary Endpoints, Pneumococcal Vaccine

1. On October 5, the company announced the topline data of VAX-31 adult Phase III OPUS-1 trial: all pre-specified primary endpoints were achieved across all age groups; among adults aged 50 and above, the 28 serotypes shared with PCV20 and/or PCV21 met the non-inferiority criteria, while the 3 serotypes unique to VAX-31 and the cross-reactive serotype 20B achieved superiority criteria.

2. On October 5, VAX-31 met pre-specified standards across immunobridging in adults aged 18 to 49, primary safety endpoint, and certain comparator results, with a safety profile similar to PCV20 and PCV21; the company expects to announce OPUS-2 and OPUS-3 results in the first half of 2027, and plans to submit a biologics license application in the first half of 2028.

3. On October 5, the company focuses on research and development of pneumococcal conjugate vaccines, with VAX-31 as a Phase III clinical-stage 31-valent candidate product that covers a broader range than similar products in development; its pipeline also includes VAX-24 and early-stage VAX-XL, targeting the approximately $8 billion global pneumococcal vaccine market.

(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)